Carmell Therapeutics Stock (NASDAQ:CTCX)

Revenue Financials Chart

Previous Close

$0.19

52W Range

$0.17 - $3.00

50D Avg

$0.35

200D Avg

$0.63

Market Cap

$5.94M

Avg Vol (3M)

$8.24M

Beta

0.51

Div Yield

CTCX Company Profile

Carmell Therapeutics Corporation (CTCX) specializes in the creation of plasma-based bioactive materials (PBMs) aimed at catalyzing tissue regeneration and repair following injury, illness, or the effects of aging. Their flagship product, CT-101, is a versatile accelerant with a dual focus. For orthopedic and dental applications, it's designed to enhance bone healing in cases such as tibia fractures, foot and ankle fusions, spinal fusions, and also serves as a dental bone graft substitute and bone void filler. Furthermore, CT-101 acts as a tissue healing accelerant, addressing conditions like androgenetic alopecia (pattern baldness) and persistent chronic wounds. Established in 2008, the company operates from its headquarters in Pittsburgh, Pennsylvania.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Sep 23, 2021

Website

CTCX Performance

CTCX Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	$1.91M	$50.32K	-
Operating Income	$-7.11M	$-5.00M	$-5.22M
Net Income	$-6.91M	$-10.37M	$-15.45M
EBITDA	$-6.81M	$-10.50M	$-15.19M
Basic EPS	$-4.83	$-0.50	$-0.74
Diluted EPS	$-4.83	$-0.50	$-0.74

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

Ticker	Company
NEUP	Neuphoria Therapeutics Inc.
MODV	ModivCare Inc.
XBIO	Xenetic Biosciences, Inc.
TECX	Tectonic Therapeutic, Inc.